The thalassemias are a group of inherited hematological disorders caused by defects in the synthesis of one or more of the hemoglobin (Hb) chains.1
Thalassemia is generally classified along a spectrum according to severity.3,4
The least serious group is thalassemia trait, an asymptomatic condition requiring no blood transfusions. A more severe form is non–transfusion-dependent thalassemia (NTDT), which has clinically relevant symptoms and may require only occasional transfusions or none. The most serious group is β-thalassemia major, or transfusion-dependent thalassemia (TDT). With severe clinical manifestations, TDT is usually diagnosed early in life, and patients require regular blood transfusions to survive.3
Patients wih abnormal synthesis within these hemoglobin chains may have NTDT: HbE/β-thalassemia, HbH/α-thalassemia, or thalassemia intermedia.2,4,5
Globally, an estimated 15 million people have thalassemia.6 Emigration of populations from South and Southeast Asia has increased the worldwide prevalence of the disease (Figure).7
For patients suspected of having thalassemia, physicians should enquire about their ethnic background, family history of hematological disorders, and dietary history.2,9
Figure. Immigration Trends Impacting Thalassemia.8
All fields are required.
You are now leaving the IronHealthalliance.com website by opening an external website independently operated and not managed by Novartis. Novartis assumes no responsibility for the site you are about to visit. If you do not wish to leave this site, click "Cancel." Otherwise, click "Continue".